Evidence map›Paper›PMID 41835005›Full record

ArticleFrontiers in cellular and infection microbiology2026

Synergistic activity of ceftazidime/avibactam combined with aztreonam against MBL-producing

Xianzhen Wei, Mingbo Liu, Runxian Tan, Peng Huang, Xia Fang, Shan Li, Meng Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xianzhen WeiDepartment of Clinical Laboratory, The First People's Hospital of Qinzhou, Qinzhou, Guangxi, China.
Mingbo LiuDepartment of Clinical Laboratory, The First People's Hospital of Qinzhou, Qinzhou, Guangxi, China.
Runxian TanDepartment of Clinical Laboratory, The First People's Hospital of Qinzhou, Qinzhou, Guangxi, China.
Peng HuangDepartment of Clinical Laboratory, The First People's Hospital of Qinzhou, Qinzhou, Guangxi, China.
Xia FangDepartment of Clinical Laboratory, The First People's Hospital of Qinzhou, Qinzhou, Guangxi, China.
Shan LiDepartment of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Meng LiDepartment of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Extensively drug-resistant Methods: The carbapenemase resistance genes (VIM, IMP, NDM, KPC, GES, OXA-40) and T3SS virulence genes of XDR-PA isolates were identified using polymerase chain reaction (PCR) and sequencing. The expression levels of efflux pump systems ( Results: A total of 32 XDR-PA strains were isolated from clinical specimens from a tertiary teaching hospital in Southwest China between October 2022 to October 2023. Among the carbapenemase detected, metallo-β-lactamase (MBL) NDM-1 and VIM-2 were detected in 26 strains (81.25%, 26/32) and 1 strain (3.13%, 1/32) respectively. The efflux pump Conclusion: The underlying resistance mechanisms of XDR-PA isolates involve the overexpression of efflux pump

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsAztreonamCeftazidimeDrug Resistance, Multiple, BacterialPseudomonas aeruginosaBacterial Proteinsbeta-LactamasesDrug CombinationsDrug SynergismHumansMicrobial Sensitivity TestsPseudomonas InfectionsVirulence FactorsAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsAztreonamBacterial Proteinsbeta-LactamasesCeftazidimeDrug CombinationsVirulence Factorscombined antimicrobial susceptibility testingextensively drug-resistant Pseudomonas aeruginosaMLSTresistance mechanismsvirulence genes

Identifiers

PMID41835005
PMCPMC12982442

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.